Dimitropoulos Anastasia, Molinari Luciano, Etter Katharina, Torresani Toni, Lang-Muritano Mariarosaria, Jenni Oskar G, Largo Remo H, Latal Beatrice
Child Development Center, University Children's Hospital Zurich, Zurich 8032, Switzerland.
Pediatr Res. 2009 Feb;65(2):242-8. doi: 10.1203/PDR.0b013e31818d2030.
We aim to determine long-term intellectual outcome of adolescents with early high-dose treated congenital hypothyroidism (CH). Sixty-three prospectively followed children with CH were assessed at age of 14 y with the Wechsler Intelligence Scale for Children-Revised and compared with 175 healthy controls. Median age at onset of treatment was 9 d (range 5-18 d) and median starting dose of levothyroxine (L-T4) was 14.7 microg/kg/d (range 9.9-23.6 microg/kg/d). Full-scale intelligence quotient (IQ) was significantly lower than in controls after adjustment for socioeconomic status (SES) and gender (101.7 versus 111.4; p < 0.0001). Children with athyreosis had a lower performance IQ than those with dysgenesis (adjusted difference 7.6 IQ scores, p < 0.05). Lower initial thyroxine (T4) levels correlated with poorer IQ (r = 0.27, p = 0.04). Lower SES was associated with poorer IQ, in particular in children with CH (interaction, p = 0.03). Treatment during childhood was not related to IQ at age 14 y. Adolescents with CH manifest IQ deficits when compared with their peers despite early high-dose treatment and optimal substitution therapy throughout childhood. Those adolescents with athyreosis and lower SES are at particular risk for adverse outcome. Therefore, early detection of intellectual deficits is mandatory in children with CH.
我们旨在确定早期接受高剂量治疗的先天性甲状腺功能减退症(CH)青少年的长期智力发育结果。对63名接受前瞻性随访的CH患儿在14岁时采用韦氏儿童智力量表修订版进行评估,并与175名健康对照进行比较。治疗开始的中位年龄为9天(范围5 - 18天),左甲状腺素(L - T4)的中位起始剂量为14.7微克/千克/天(范围9.9 - 23.6微克/千克/天)。在对社会经济地位(SES)和性别进行调整后,全量表智商(IQ)显著低于对照组(101.7对111.4;p < 0.0001)。甲状腺缺如的患儿其操作智商低于甲状腺发育不全的患儿(调整后的差异为7.6个智商分数,p < 0.05)。较低的初始甲状腺素(T4)水平与较差的智商相关(r = 0.27,p = 0.04)。较低的SES与较差的智商相关,尤其是在CH患儿中(交互作用,p = 0.03)。儿童期的治疗与14岁时的智商无关。尽管在儿童期进行了早期高剂量治疗和最佳替代治疗,但CH青少年与同龄人相比仍表现出智商缺陷。那些甲状腺缺如且SES较低的青少年出现不良结局的风险尤其高。因此,对CH患儿进行智力缺陷的早期检测是必不可少的。